Streamex Corp. is a technology company that operates two principal lines of business: tokenized asset finance and biomedical technology. The tokenized asset finance business runs the Streamex Exchange platform which enables the issuance, trading, and custody of digital tokens backed by tangible assets such as gold and other commodities. The platform supports onboarding of assets, smart contract enforcement, investor verification, and settlement workflows. The biomedical technology business focuses on advanced signal processing solutions for electrophysiology through the PURE EP™ platform which delivers high fidelity cardiac signal data to clinicians during ablation procedures for treating arrhythmias such as ventricular tachycardia and atrial fibrillation. The business also pursues research into proprietary software algorithms that aim to improve ablation specificity and long term outcomes.

Revenue is generated primarily from the Streamex Exchange platform through issuance fees on new token creation, secondary trading and exchange related transaction fees, and spreads from yield generating activities. Additional revenue streams include listing fees for new tokens, transaction and trading fees, liquidity provisioning incentives, and underwriting and origination fees for private placement and capital markets access services. The platform also expects to earn revenue from subscription based access to data analytics tools and from custodial service fees paid by third party service providers. The biomedical technology business may generate revenue from licensing of its signal processing algorithms, sales of related software, and potential future sales of medical devices but currently focuses on research and development activities.

The company operates through the following segments:

• Tokenized Asset Finance: This segment provides the Streamex Exchange platform that enables the issuance, trading, and custody of digital tokens backed by tangible assets such as gold and other commodities. It supports asset onboarding, smart contract generation, investor onboarding with AML/KYC checks, settlement processing, and reporting functions. Revenue is derived from issuance fees, trading fees, listing fees, liquidity incentives, and yield spreads generated through gold leasing partnerships.

• Biomedical Technology: This segment focuses on advanced signal processing solutions for electrophysiology through the PURE EP™ platform which delivers high fidelity cardiac signal data to clinicians during ablation procedures for treating arrhythmias such as ventricular tachycardia and atrial fibrillation. The segment also conducts research into proprietary software algorithms that aim to improve ablation specificity and long term outcomes. Potential revenue sources include licensing of algorithms, sales of software, and future medical device sales.

In the digital asset infrastructure sector Streamex Corp. positions itself as an emerging provider of tokenized real world asset solutions with a focus on gold backed tokens and yield generation competing against established platforms such as Pax Gold, Securitize, Tradeweb, Tokeny, Polymesh, and Spydra. Its competitive advantages include a proprietary tokenization protocol that integrates with LBMA accredited custodians, a strategic partnership with Monetary Metals for gold leasing yield, and a compliant infrastructure designed for institutional investors. In the biomedical technology arena the company competes with other electrophysiology signal processing providers and differentiates itself through its high fidelity PURE EP™ platform, its ongoing research collaborations with institutions such as Mayo Foundation, and its portfolio of issued patents covering signal acquisition and processing techniques.

The Streamex Exchange platform serves accredited and qualified investors, institutional participants such as asset managers and family offices, third party issuers looking to tokenize real world assets, and financial intermediaries seeking custody and trading infrastructure for commodity linked tokens. The biomedical technology business serves electrophysiologists working in hospitals and outpatient clinics, medical device manufacturers that require advanced signal data for product development, and research institutions studying cardiac electrophysiology and ablation techniques.